Steven Horwitz

Dec 17, 2024 | onclive.com | Steven Horwitz

Steven Horwitz, MD, presents the final results of the Phase 2 PRIMO trial, highlighting the efficacy and safety of duvelisib as a promising treatment option for relapsed/refractory peripheral T-cell lymphoma, with insights into overall response rates, progression-free survival, and adverse event management.

Nov 15, 2024 | nature.com | Steven Horwitz |Ajit J Nirmal |Jahan A. Rahman |Ran Xu |Esther N. Drill |David Fisher | +7 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03076-6, published online 17 June 2024. In the version of this article initially published, there were two typographical errors in the SS (Sezary syndrome) row in the Arm A section of Table 3. The PRR (partial response rate) for both all patients and at MTD only should have been shown as “50 (2)” instead of “29 (2)” and “40 (2)”, respectively. The errors do not affect the conclusions of the study.

Oct 13, 2024 | nature.com | Jennifer K Lue |Alexander P Boardman |Steven Horwitz |Andrew M. Intlekofer |Anita Kumar |Ariela Noy | +4 more

Dear Editor,High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH) is a group of aggressive lymphomas that are associated with poor outcomes when treated with R-CHOP [1, 2]. Conflicting data exists regarding the outcomes of HGBCL with MYC and BCL2 rearrangements (DH-BCL2) as compared to HGBCL with MYC and BCL6 translocations (DH-BCL6) [3,4,5,6].

Jun 17, 2024 | nature.com | Steven Horwitz |Ajit J Nirmal |Jahan A. Rahman |Ran Xu |Esther N. Drill |David Fisher | +7 more

AbstractPI3K-δ inhibitors have shown impressive activity in lymphoid malignancies but have been hampered by autoimmune and infectious toxicities, leading to market withdrawals. We previously demonstrated activity of the PI3K-δγ inhibitor duvelisib in T cell lymphomas (TCLs) that was associated with inflammatory adverse events.

Mar 26, 2024 | ascopubs.org | Steven Horwitz

1,2 In the landmark ECHELON-2 study, brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) resulted in significant improvements in progression-free survival (PFS) and OS.3 The greatest benefits were seen in ALCL, setting the stage for subtype-specific therapy in PTCL.3 In the past decade, we have learned that PTCL derived from TFH cells, such as nodal TFH lymphoma (TFHL) angioimmunoblastic-type (AITL), nodal TFHL follicular-type, and nodal TFHL not...